Ticker

ATX-04 is a selective β2-adrenergic agonist with human proof-of-concept data demonstrating improved muscle function and enhanced response to enzyme replacement therapy MIAMI, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (OTC: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for rare and neurologic diseases, today…

Institutional and Insider Ownership 17.3% of Avenue Therapeutics shares are held by institutional investors. 5.6% of Endonovo Therapeutics shares are held by insiders. Comparatively, 8.6% of Avenue Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over

Risk and Volatility Avenue Therapeutics has a beta of -0.51, indicating that its share price is 151% less volatile than the S&P 500. Comparatively, ObsEva has a beta of 0.68, indicating that its share price is 32% less volatile than the S&P 500. Valuation and Earnings This table compares Avenue Therapeutics and ObsEva"s revenue, earnings

Profitability This table compares NexImmune and Avenue Therapeutics' net margins, return on equity and return on assets. Net Margins Return on Equity Return on Assets NexImmune N/A -534.32% -213.72% Avenue Therapeutics N/A -471.57% -296.50% Volatility and Risk NexImmune has a beta of 1.98, suggesting that its share price is 98% more volatile than the S&P